Enhancing Treatment of BRCA-Deficient Breast and Ovarian Cancers
Peter M. Glazer, M.D., Ph.D., Professor and Chair of Therapeutic Radiology
Dr. Glazer’s study is moving a powerful new antibody (a protein made by immune cells to attack disease agents such as cancer cells) toward clinical application for improving breast and ovarian cancer treatments.
He discovered that this antibody, 3E10, can increase the vulnerability of various types of cancer cells to radiation and chemotherapy. Early evidence shows this effect is greater in breast and ovarian cancer cells related to mutations of two particular genes, BRCA1 and BRCA2. Inherited mutations involving these genes increase risk for breast and ovarian cancers, and many non-familial breast and ovarian cancers are associated with cell-repair defects involving mutations of these two genes.
The ultimate goal is to provide new, more effective treatments for women with breast and ovarian cancers.
This study is funded in conjunction with the Yale Comprehensive Cancer Center.